Safety and Efficacy of Antimicrobial Peptides against Naturally Acquired Leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 641-643

  Alberola, J ^a   Rodriguez A ^a   Francino, O ^a   Roura, X ^a   Rivas, L ^b   Andreu, D ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CECROPIN; DERMASEPTIN; GOMISIN; MEGLUMINE ANTIMONATE; MELITTIN; MILTEFOSINE; OCTYL CECROPIN(1 7)MELITTIN(2 9); OCTYL-CECROPIN(1-7)MELITTIN(2-9); PEPTIDE YY;

ANIMAL; ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOG; DOG DISEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; PARASITOLOGY; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DOG DISEASES; DOGS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL;

EID: 0942301299     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.641-643.2004     Document Type: Article

References (37)

1. Akuffo, H., D. Hultmark, A. Engstom, D. Frohlich, and D. Kimbrell. 1998. Drosophila antibacterial protein, cecropin A, differentially affects non-bacterial organisms such as Leishmania in a manner different from other amphipathic peptides. Int. J. Mol. Med. 1:77-82.
2. Altet, L., O. Francino, L. Solano-Gallego, C. Reníer, and A. Sanchez. 2002. Mapping and sequencing of the canine NRAMP1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect. Immun. 70:2763-2771.
3. Andreu, D., and L. Rivas. 1998. Animal antimicrobial peptides: an overview. Biopolymers 47:415-433.
4. Baneth, G., and S. E. Shaw. 2002. Chemotherapy of canine leishmaniosis. Vet. Parasitol. 106:315-324.
5. Bauer, R. J., M. L. White, N. Wedel, B. J. Nelson, N. Friedmann, A. Cohen, W. N. Hustinx, and A. H. Kung. 1996. A phase 1 safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock 5:91-96.
6. Bieche, I., B. Parfait, V. Le Doussal, M. Olivi, M. C. Rio, R. Lidereau, and M. Vidaud. 2001. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res. 61:1652-1658.
7. Carrió, J., and M. Portús. 2 May 2002, posting date. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol. 2:11. [Online.]
8. Chicharro, C., C. Granata, R. Lozano, D. Andreu, and L. Rivas. 2001. N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob. Agents Chemother. 45:2441-2449.
9. Diaz Achirica, P., J. Ubach, A. Guinea, D. Andreu, and L. Rivas. 1998. The plasma membrane of Leishmania donovani promastigotes is the main target for CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide. Biochem. J. 330:453-460.
10. Feder, R., A. Dagan, and A. Mor. 2000. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J. Biol. Chem. 275:4230-4238.
11. Hernandez, C., A. Mor, F. Dagger, P. Nicolas, A. Hernandez, E. L. Benedetti, and I. Dunia. 1992. Functional and structural damage in Leishmania mexicana exposed to the cationic peptide dermaseptin. Eur. J. Cell Biol. 59:414-424.
12. Jha, T. K., S. Sundar, C. P. Thakur, P. Bachmann, J. Karbwang, C. Fischer, A. Voss, and J. Berman. 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341:1795-1800.
13. Koczulla, A. R., and R. Bals. 2003. Antimicrobial peptides: current status and therapeutic potential. Drugs 63:389-406.
14. Kustanovich, I., D. E. Shalev, M. Mikhlin, L. Gaidukov, and A. Mor. 2002. Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J. Biol. Chem. 277:16941-16951.
15. Lillard, J. W., P. N. Boyaka, O. Chertov, J. J. Oppenheim, and J. R. McGhee. 1999. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl. Acad. Sci. USA 96:651-656.
16. 2-terminal alpha-helical domain 1-18 of dermaseptin is responsible for antimicrobial activity. J. Biol. Chem. 269:1934-1939.
17. Nicolas, P., and A. Mor. 1995. Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu. Rev. Microbiol. 49:277-304.
18. Raj, P. A., and A. R. Dentino. 2002. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol. Lett. 206:9-18.
19. Rivas, L., M. Velasco, J. M. Díaz-Guerra, P. Díaz-Achirica, D. Andreu, and L. Boscá. 1996. CA(1-8)M(1-18), a cecropin A-melittin hybrid peptide, induces nitric oxide, apoptosis and leishmanicidal activity in macrophages, p. 755-756. In R. Ramage and R. Epton (ed.), Peptides. Mayflowers Scientific Ltd., Kingswinford, United Kingdom.
20. Sacks, D., and A. Sher. 2002. Evasion of innate immunity by parasitic protozoa. Nat. Immunol. 3:1041-1047.
21. Salzet, M. 2002. Antimicrobial peptides are signaling molecules. Trends Immunol. 23:283-284.
22. Silva, P. I., S. Daffre, and P. Bulet. 2000. Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family. J. Biol. Chem. 275:33464-33470.
23. Slappendel, R. J., and L. Ferrer. 1998. Leishmaniasis, p. 450-458. In C. E. Green (ed.), Infectious diseases of the dog and cat, 2nd ed. W. B. Saunders Company, Philadelphia, Pa.
24. Solano-Gallego, L., J. Llull, G. Ramos, C. Riera, M. Arboix, J. Alberola, and L. Ferrer. 2000. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet. Parasitol. 90:37-45.
25. Solano-Gallego, L., P. Morell, M. Arboix, J. Alberola, and L. Ferrer. 2001. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J. Clin. Microbiol. 39:560-563.
26. Solano-Gallego, L., C. Riera, X. Roura, L. Iniesta, M. Gallego, J. E. Valladares, R. Fisa, S. Castillejo, J. Alberola, L. Ferrer, M. Arboix, and M. Portus. 2001. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment. Vet. Parasitol. 96:265-276.
27. Sundar, S., D. K. More, M. K. Singh, V. P. Singh, S. Sharma, A. Makharia, P. C. Kumar, and H. W. Murray. 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31:1104-1107.
28. Valladares, J. E., C. Riera, J. Alberola, M. Gallego, M. Portus, C. Cristofol, C. Franquelo, and M. Arboix. 1998. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet. Parasitol. 75:33-40.
29. Valladares, J. E., C. Riera, P. Gonzalez Ensenyat, A. Diez-Cascon, G. Ramos, L. Solano-Gallego, M. Gallego, M. Portus, M. Arboix, and J. Alberola. 2001. Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Vet. Parasitol. 97:15-21.
30. Velasco, M., M. J. Diaz Guerra, P. Diaz Achirica, D. Andreu, L. Rivas, and L. Bosca. 1997. Macrophage triggering with cecropin A and melittin-derived peptides induces type II nitric oxide synthase expression. J. Immunol. 158:4437-4443.
31. Vizioli, J., and M. Salzet. 2002. Antimicrobial peptides versus parasitic infections? Trends Parasitol. 18:475-476.
32. Vouldoukis, I., Y. Shai, P. Nicolas, and A. Mor. 1996. Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett. 380:237-240.
33. Wade, D., A. Boman, B. Wahlin, C. M. Drain, D. Andreu, H. G. Boman, and R. B. Merrifield. 1990. All-D amino acid-containing channel-forming antibiotic peptides. Proc. Natl. Acad. Sci. USA 87:4761-4765.
34. World Health Organization. 2002. Annex 3. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. In The World Health Report 2002, p. 192-197. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/whr/2002/en/whr2002_annex3.pdf.
35. World Health Organization. May 2000, posting date. The leishmaniases and Leishmania/HIV co-infections. Fact sheet no. 116. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/inf-fs/en/fact116.html.
36. Yang, D., A. Biragyn, L. W. Kwak, and J. J. Oppenheim. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23:291-296.
37. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.